15. Dummer R., Kohl O., Gillessen J., Kägi M.K., Burger G.: Peripheral blood mononuclear cells in patients with nonleukaemic cutaneous T cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2like cytokine pattern on stimulation. Arch Dermatol 1993;129:443-436. 16. Schneider T., Lang A:B:, Carballido J.M., Santamaria Babi L.F., Dudler T., Kägi M.K., Blaser K., Suter M.: Human monoclonal or polyclonal antiodies recognize predominantly discontinous epitopes on bee venom phospholipaseA2. J Allergy clin Immunol11994;94:61-70. 17. Kägi M.K., Wüthrich B., Montano E., Barandun J., Blaser K., Walker C.: Differential cytokine profiles in peripheral blood andskinbiopsies from patients with different forms of atopicdermatitis, psoriasis and normal individuals. Int. Arch Allergy Immunol 1994;103:332-340. 18. Eckstein P., Huzar A., Kägi M.K., Wüthrich B.: Millet seed: A seldom ingestive and inhalative allergen? Allergo Journal 1994;3:189-191. 19. Kägi M.K., Wüthrich B., S.G.O. Johansson: Campari-Orange anaphylaxis due to carmine allergy. Lancet 1994;344:60-61. 20. Wüthrich B., Joller-Jemelka H., Kägi M.K.: Soluble ICAM-1 is another possible serum marker for acitivity in atopic dermatitis. Allergy, 1995;50:8889. 21. Gloor M., Kägi M.K., Wüthrich B., Puppy seed anaphylaxis. Schweiz. Med. Wochenschr. 1995;125:1434-1437. 22. Kägi M.K., Wüthrich B., Trüeb R., Burg G.: Two cases of confluent and reticulated papillomatosisassociated with atopy. Successful treatment with topical urea and tretinoin. Brit J Dermatol 1996;134:372-382. 23. Bächli E., Kägi M.K., Krause M.: Visceral andneurological complications in primaryvaricella infections of the adults. Schweiz. Med. Wochenschr. 1996:126:440-446. 24. Kägi M.K., Wüthrich B.: Levels of soluble ICAM-1 are slightly elevated in the serum of patients with atopic dermatitis. Int. Arch Allergy Immunol, 1996;110:298. 25. Wüthrich B., Kägi M.K., Stücker W.: Anaphylactic reactions to ingested carmin(E120). Allergy, 1997;52:1133-1137. 26. Kägi M.K.: Aktuelle Empfehlungen zur Therapie des atopischen Ekzems. Allergologie, 1998;21:223-337. 27. Kägi M.K.: Die orale Hyposensibilisierung und andere Formen der lokalen Immunotherapie. Position Paper der SGAI. Schweiz. Aerztezeitung, 1998;79:1475-1481. 28. Kägi M.K., Wortmann F., Wüthrich B.: Spezifische orale Immunotherapie. In: Manuale allergologicum. Eds. Fuchs E. and Schulz KH., Dustri Verlag Dr. Karl Feistle, Deisenhofen, 1998. 29. Kägi M.K.: Therapeutisches Management der Neurodermitis atopica. Therapeutische Umschau, 1998; 55:493-497. 30. Zurbriggen B., Wüthrich B., Cachelin A.B., Willi P.B., Burg G., Kägi M.K.: Comparison of two galenical fromultaionsof Ciclosporin A in the treatment of severe atopic dermatitis: A double blind, single-centre crossover pilot study; Dermatology, 1999;198:56-60.
RkJQdWJsaXNoZXIy MjYwOTU=